Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortality risks among women with hormone-sensitive breast cancer. However, adherence to AET is suboptimal. To guide the development of theory-based interventions to enhance AET adherence, we conducted a stu...
Main Authors: | Brittany Humphries, Stéphanie Collins, Laurence Guillaumie, Julie Lemieux, Anne Dionne, Louise Provencher, Jocelyne Moisan, Sophie Lauzier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Pharmacy |
Subjects: | |
Online Access: | http://www.mdpi.com/2226-4787/6/2/53 |
Similar Items
-
Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01) -
The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy
by: Giorgio Dell’Acqua, et al.
Published: (2020-11-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01) -
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
by: Li Li, et al.
Published: (2018-10-01) -
Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01)